Heart attacks and strokes are among the leading causes of death globally, with millions suffering from cardiovascular diseases (CVD) every year. There are more than seven million people in the UK alone, with about 100,000 patients experiencing heart attacks annually. However, a group of researchers at University College London (UCL) estimate that one 'polypill' taken daily day could eliminate a majority of these cases dramatically lowering death tolls.

The proposed polypill, a combination of a statin and three blood pressure-lowering drugs, has been under study for over two decades. Experts argue that introducing this pill universally for individuals aged 50 and above could be more effective than the current NHS Health Check, which assesses risk factors every five years for those aged between 40 and 74.

Studies have repeatedly proven the effectiveness of the polypill in preventing CVD. A groundbreaking 2019 study in The Lancet found that five years' use of the polypill cut the risk of heart attack and stroke by a third. In addition, previous modelling analyses have estimated that if given universally to people over 55, the polypill might be able to prevent 80% of heart attacks and strokes.

Today, the NHS Health Check follows a risk-based model in which patients are tested for CVD risk factors and treated with drugs accordingly. Yet, as per UCL's study, this system has serious flaws:

Low Uptake: Just 40% of those eligible for the NHS Health Check choose to have it, leaving a considerable number of at-risk patients undiagnosed and untreated.

Ineffective Prediction of Risk: The majority of heart attacks and strokes happen to people at average risk levels, thus making it challenging to identify the need for intervention effectively.

Limited Effectiveness: Even at maximum take-up, the NHS Health Check programme is predicted to have fewer health impacts compared to a polypill initiative applied to the whole population.

Simplicity and Affordability of the Polypill Strategy

One of the big benefits of the polypill is that it is so easy. In contrast to the existing screening-based model, the polypill scheme would not involve complicated medical tests or lengthy risk assessments. Instead, people reaching 50 would just have to fill out a few questions to determine possible side effects before they were prescribed.

Professor Aroon Hingorani of the UCL Institute of Cardiovascular Science, one of the strongest proponents of this scheme, says:

"Finally, the time is now to do much better on prevention. A population approach would prevent a lot more heart attacks and strokes than is done today with a strategy of trying to target a smaller group only."

Aside from the possible health implications, the polypill is also an economic solution. The drugs used are off-patent, thus cheap to produce and distribute. With the vast economic cost of managing CVD-related illnesses, a preventive model could result in substantial cost-saving for the NHS in the future.

The polypill has been proven to be effective by numerous international trials. In 2019, a randomised trial in rural Iran discovered that participants who took the polypill for five years had a 34% reduced risk of having a heart attack or stroke compared to non-participants.

Likewise, modelling research has indicated that even if only 8% of people aged over 50 took up the polypill regimen, it would still be more beneficial to their health than the NHS Health Check programme.

Is This a Case of Over-Medicalisation?

One of the main objections to the polypill strategy is the suggestion that it might result in the unnecessary medicalisation of a significant proportion of the population. But, it is argued, it should be considered as a preventative measure, not as mass medication.

Professor Sir Nicholas Wald of UCL's Institute of Health Informatics explains:

"Instead of being a 'medicalisation' of a significant proportion of the population, a polypill programme is a prevention measure to prevent an individual from becoming a patient."

He compares it with public health measures like water fluoridation or compulsory seatbelts—interventions that have been shown to have a significant impact in reducing public health danger at low individual cost.

With the evidence in favour of the polypill's effectiveness and viability overwhelming, experts are calling on the NHS to act now. It is their belief that substituting the NHS Health Check with a polypill-based prevention program could be the UK government's flagship policy under its pledge to put disease prevention ahead of cure.

As Professor Hingorani points out, "The status quo is not a justifiable option." With CVD still a major cause of death globally, taking a population-wide polypill approach could be a turning point for preventative medicine, potentially saving thousands of lives annually. The question now is whether the NHS will take up this call and establish a policy with the potential to transform the prevention of cardiovascular disease on a national level.

UK’s National Institute for Health and Care Excellence (NICE) has advised healthcare professionals to look for signs of obsessive-compulsive disorder (OCD) and body dysmorphic disorder (BDD) in people seeking cosmetic procedures such as Botox and fillers.

The recommendation is part of a draft guideline aimed at earlier identification of the two conditions, which can remain undiagnosed for years because people may hide symptoms due to shame or embarrassment. In addition, the cosmetic industry is vastly unregulated, increasing potential health risk.

“People with obsessive-compulsive disorder (OCD) and body dysmorphic disorder (BDD) could be identified earlier and offered more appropriate treatment,” said the draft NICE guidance published today.

What Does The NICE Guidance Say?

Also read: Ferritin Face: Can Pale Skin Signal Iron Deficiency?

NICE’s new draft recommends considering assessment for OCD or BDD among people with depression, anxiety, autism or ADHD, as well as those seeking cosmetic procedures.

The committee said symptoms can be overlooked or attributed to other conditions, delaying diagnosis and treatment.

"People with obsessive-compulsive disorder and body dysmorphic disorder can experience symptoms for a long time before they receive the right diagnosis and support. These conditions are often misunderstood, and many people find them difficult to talk about because of embarrassment, shame or fear of being judged,” Eric Power, interim director of the Centre for Guidelines at NICE, said.

Mental Health Checks Before Botox And Fillers

Healthcare professionals providing cosmetic treatments, including surgeons, dentists and dermatologists, would be advised to ask structured questions about appearance-related concerns and document their findings.

If responses suggest possible BDD, NICE recommends specialist assessment rather than proceeding with the cosmetic procedure at that stage.

Read More: More Women Buying Testosterone Without Prescription: Can It Help With Menopause?

The committee noted that cosmetic procedures rarely improve the underlying condition and may sometimes worsen symptoms.

A 2024 systematic review and meta-analysis estimated that 18.6% of people attending aesthetic and reconstructive plastic surgery services had clinically significant BDD symptoms, compared with around 2% of adults in the wider population.

"Our draft recommendations aim to help healthcare professionals recognize symptoms earlier, ask the right questions and support people to access appropriate treatment sooner," Power said.

"Earlier identification can help ensure people receive care that reflects their needs, preferences and circumstances, rather than waiting until symptoms become more severe or reach crisis point," he added.

New Approach To OCD Treatment

The draft guideline also proposes a personalized “matched care” approach to OCD treatment, with interventions based on a person’s clinical needs, treatment history and preferences rather than a fixed sequence.

For children and young people with OCD, the draft recommends family-based cognitive behavioral therapy for many patients.

What Are OCD And BDD?

OCD affects an estimated 1.2% of the population. It involves unwanted, distressing thoughts, images, urges or doubts, often followed by repetitive behaviors or mental rituals such as checking, washing, counting or seeking reassurance.

BDD involves excessive preoccupation with perceived flaws in appearance, which can cause significant distress and interfere with daily life. Research suggests it affects around 2% of adults.

The consultation on the draft NICE guideline is open until October 21, 2026.

Endometriosis does not usually present with typical symptoms. Due to this, getting a diagnosis can take years.

This may change soon as a team of Australian researchers recently developed an artificial intelligence tool that can identify two major imaging signs of advanced endometriosis in just 18 milliseconds.

Called EndoFusion, the tool was developed by researchers at Adelaide University as part of the IMAGENDO research programme. The findings were published in Artificial Intelligence in Medicine.

The 18-millisecond figure refers to how quickly the AI analyses a scan and produces its assessment. It does not mean that a woman can currently walk into a clinic and receive a confirmed diagnosis in 18 milliseconds.

The technology is still in development and requires further testing before it can become part of routine clinical diagnosis.

Endometriosis May Take Years To Diagnose

Endometriosis occurs when tissue similar to the lining of the uterus grows outside the uterus, commonly affecting areas such as the ovaries and fallopian tubes.

It can cause severe period pain, pelvic pain, heavy bleeding, fatigue, pain during sex and difficulty becoming pregnant.

Diagnosis is challenging as symptoms can vary, and some women have little or no visible symptoms on conventional imaging.

Research has consistently found substantial diagnostic delays. A systematic review found delays ranging from months to as long as 12 years.

In Australia, women reportedly wait an average of around six and a half years for a diagnosis, according to Endometriosis Australia.

Also read: 22-Year-Old Frozen Embryo Produced A Healthy Baby: Does An Embryo Have An Expiry Date?

More About The AI Tool Work

EndoFusion was trained using four datasets containing more than 9,000 pelvic MRI scans and over 800 transvaginal ultrasound scans as they can identify different signs of endometriosis effectively.

A patient who receives only one type of scan may therefore have some symptoms of the disease missed.

Associate Professor Jodie Avery of Adelaide University's Robinson Research Institute said, “Current scanning methods each have their own strengths when it comes to detecting two common markers that indicate the likelihood of endometriosis and patients will often only have access to one of them.”

She added, “This means that some patients could be disadvantaged if they are scanned by the less optimal option for their particular signs. Some of the imaging tools also rely on operator experience and can be costly.”

In its early evaluation, EndoFusion correctly distinguished positive and negative cases 83% of the time, performing better than the other AI models researchers compared it with.

Lead author Dr Yuan Zhang said, “This is a positive step forward and moves us closer to a future where an AI tool can help clinicians to provide a faster, more accurate diagnosis without the need for surgery.” However, 83% accuracy is not enough to replace clinical diagnosis.

The researchers say the next step is to expand the dataset and incorporate additional markers of endometriosis to improve classification accuracy.

Also read: HHS Cancels Maternal & Infant Health Grants To Focus On Sperm Testing And ED: Here's Why

Could It Reduce The Need For Surgery?

Endometriosis diagnosis has historically relied heavily on imaging and, in some cases, laparoscopy, in which a camera is inserted through a small abdominal incision to look for lesions.

A reliable non-invasive tool could help doctors identify women who need specialist assessment sooner and potentially reduce unnecessary invasive investigations.

As Avery said, “The development of accurate, non-invasive early diagnostic methods is critical to shorten the diagnostic timeline and reduce associated costs.”

Pancreatic cancer is one of the most difficult cancers to detect in its early stages. By the time it is diagnosed, the disease may have already spread, limiting treatment options and lowering survival.

Now, a novel blood test called Panxeon, developed by researchers at City of Hope, could offer a way to detect pancreatic cancer earlier.

Panxeon is an investigational liquid biopsy designed to detect pancreatic cancer, including stage 1 and 2 disease, using a blood sample.

The test also showed potential for identifying high-grade dysplasia, a precancerous condition sometimes considered “stage 0” pancreatic cancer.

In a study of nearly 1,800 patients across the US, Europe and Asia, published in Nature Medicine, the blood test correctly identified stage 1 and 2 pancreatic cancer in 87% of cases. Its false-positive rate was 3% among people in low-risk groups and 16% among those in high-risk groups.

Panxeon also detected high-grade dysplasia more than 64% of the time. This could help doctors identify which pancreatic cysts may require closer monitoring or further intervention before invasive cancer develops.

Also read: Meet Audrey Zheng: 17-YO Who Developed Blood Test For Pancreatic Cancer That Correctly Identified 87% Of Patients

How Does Panxeon Detect Pancreatic Cancer?

Pancreatic cancer has one of the lowest survival rates among cancers. Only 14% of patients survive five years after diagnosis, according to the US National Cancer Institute.

Panxeon assesses three biological signals associated with pancreatic cancer: circulating microRNAs, exosomal microRNAs and a protein called CA19-9.

The test then uses artificial intelligence to combine these measurements into a single score estimating a person's risk of pancreatic cancer.

“Pancreatic cancer remains so deadly largely because we find it after the window for cure has begun to close,” said senior author Ajay Goel, chair of the Department of Molecular Diagnostics and Experimental Therapeutics at City of Hope.

“For patients, these findings represent progress toward finding pancreatic cancer before symptoms appear and while more treatment options remain available,” he added.

According to the researchers, Panxeon is the first investigational test to combine these three biomarkers into a single blood test.

However, Panxeon is not intended to replace imaging or other diagnostic tests. Instead, it could potentially help identify people at higher risk who need further evaluation, said Goel.

Who Could Benefit From the Test?

Read More: Former US Senator Ben Sasse Opens Up About Battle With Terminal Stage 4 Pancreatic Cancer

Early detection of pancreatic cancer has been a longstanding research challenge, with previous blood-based tests failing to provide sufficient accuracy.

The researchers said Panxeon's approach differs by combining multiple biomarkers and evaluating the test in people with risk factors such as inherited or familial risk, pancreatic cysts and chronic pancreatitis, rather than relying only on healthy controls.

“Most biomarkers tell you one part of the story. Combining multiple biological signals gives us a clearer picture of what may be happening in the pancreas,” Goel said.

People who may potentially benefit from such testing include those with an inherited risk or family history of pancreatic cancer, pancreatic cysts or chronic pancreatitis.

These groups are often monitored using imaging and other tests. A reliable blood test could eventually help identify who needs further evaluation.

“A stage shift is not just a statistic,” Goel said. “The earlier we find pancreatic cancer, the greater the chance that meaningful intervention is still possible.”

Pancreatic Cancer: Know The Warning Signs

READ: Daraxonrasib: US FDA Approves Once-Daily Pill for Metastatic Pancreatic Cancer

Pancreatic cancer can begin with few or nonspecific symptoms, making early diagnosis difficult. Symptoms may become more apparent as the disease progresses.

Symptoms that should not be ignored include:

• Abdominal or back pain
• Unexplained weight loss
• Jaundice
• Changes in urine or stool.